08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Cancer Research UK, Medivir deal

Medivir terminated an April partnership with Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm to develop and commercialize small molecules that target cell surface protein ADAM metallopeptidase domain 8 (ADAM8)....
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Cancer Research UK, Medivir deal

Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm partnered with Medivir to develop small molecules that target cell surface protein ADAM metallopeptidase domain 8 (ADAM8). Under the two-year deal, Medivir...
07:00 , Sep 16, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology ADAM8; tumor necrosis factor-a (TNF-a)...